Last week, readers were most interested in updates provided by Thermo Fisher Scientific, Abbott, and others at the JP Morgan Healthcare Conference.

News items for in vitro diagnostics industry for the week of Jan. 10, 2022.

The owner was accused of bundling COVID-19 testing with other medically unnecessary forms of testing.

The new procurement follows a December announcement that the White House would send 500 million free rapid tests to Americans.

The assay will be designed for self-testing and is expected to be sensitive enough to detect HIV during acute infection, treatment, and viral rebound.

The company projected full year 2021 revenues of $109 million to $111 million, up from $86.4 million in 2020.

Highlights of the third day included Quest's view on its information and services business and Quidel's take on the proposed Ortho Clinical buy.

Following the Czech Republic, the RT-PCR test, which requires no RNA extraction, will likely launch in Hungary, Slovakia, Ukraine, and Russia.

The company said that it contracted 16 Pheno instruments with new US customers during Q4 and ended 2021 with 81 instruments in its US backlog.

The company said the offering will help raise capital while allowing existing shareholders to maintain their proportional ownership in the company.